References
- Diniz Gomes D, Gold K, Gibbons D, et al. Non-small cell lung cancer. the MD Anderson manual of medical oncology. Internet]. 3rd ed. New York: McGraw-Hill; 2016 [cited 2021 Mar 30]. Available from https://accessmedicine.mhmedical.com/book.aspx?bookID=1772
- National Comprehensive Cancer Network. NCCN guidelines - non-small cell lung cancer (version 2.2021) [Internet]. 2021. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
- Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1–Selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–1339.
- Seung SJ, Hurry M, Hassan S, et al. Cost-of-illness study for non-small-cell lung cancer using real-world data. Curr Oncol. 2019;26(2):102–107.
- National Cancer Database (NCDB) - Commission on Cancer (CoC). NCDB public benchmark reports [Internet]. American College of Surgeons. cited 2021 Apr 19]. Available from 2021 Apr 19: https://reportsncdb.facs.org/BMPub/
- Holmes M, Mahar A, Lum T, et al. P1.09-26 expression rates in different NSCLC specimens. 2019. [Internet]. Barcelona, Spain. [cited 2021 Apr 19]. Available from DOI:10.1016/j.jtho.2019.08.1055.
- Agency for Healthcare Research and Quality. National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2017. [Internet]. cited 2020 Mar 24]. Available from 2020 Mar 24: http://hcupnet.ahrq.gov/
- IBM Watson Health. IBM Micromedex RED BOOK database [Internet]. cited 2021 Apr 19]. Available from 2021 Apr 19: https://www.ibm.com/products/micromedex-red-book
- Centers for Medicare & Medicaid Services. Medicare physician fee schedule. [Internet]. 2020 cited 2020 Mar 24]. Available from 2020 Mar 24: https://www.cms.gov/apps/physician-fee-schedule/
- Reck M, Rodríguez-Abreu D, Robinson AG, et al., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
- Gadgeel S, Rodríguez-Abreu D, Speranza G, et al., Updated Analysis From KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505–1517.
- Paz-Ares L, Luft A, Vicente D, et al., Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051.
- Socinski MA, Jotte RM, Cappuzzo F, et al., Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
- West H, McCleod M, Hussein M, et al., Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–937.
- Hellmann MD, Paz-Ares L, Bernabe Caro R, et al., Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031.
- Paz-Ares L, Ciuleanu T-E, Cobo M, et al., First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211.
- US Bureau of Labor Statistics. Consumer price index data tables. [Internet]. cited 2022 Mar 30]. Available from 2022 Mar 30: https://www.bls.gov/cpi/.
- Chen Y, Criss SD, Watson TR, et al. Cost and Utilization of lung cancer end-of-life care among racial-ethnic minority groups in the United States. The Oncologist. 2020;25(1):e120–e129.
- Buja A, Rivera M, De Polo A, et al. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: a whole-disease model. Thorac Cancer. 2021;12(1):13–20.